Log In
Print
BCIQ
Print
Print this Print this
 

DCVAC/PCa

  Manage Alerts
Collapse Summary General Information
Company Sotio a.s.
DescriptionActive cellular immunotherapy for prostate cancer that uses a patient's dendritic cells to induce an immune reaction against presented tumor antigens
Molecular Target
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationProstate cancer
Indication DetailsFirst-line treatment of metastatic castration-resistant prostate cancer (CRPC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today